Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

In-Jin Jang

Showing results (121-130 of 292) with videos related to

Pageof 30
Sort By:
Pharmaceuticals (Basel, Switzerland)|November 10, 2022
Safety, Tolerability, and Serum/Tear Pharmacokinetics of Human Recombinant Epidermal Growth Factor Eyedrops in Healthy SubjectsHyounggyoon Yoo, Seonghae Yoon, In-Jin Jang, et al.
Drug Design, Development and Therapy|February 14, 2015
A fixed-dose combination tablet of gemigliptin and metformin sustained release has comparable pharmacodynamic, pharmacokinetic, and tolerability profiles to separate tablets in healthy subjectsSang-In Park, Howard Lee, Jaeseong Oh, et al.
Pharmaceutics|September 28, 2021
Prediction of Drug-Drug Interaction Potential of Tegoprazan Using Physiologically Based Pharmacokinetic Modeling and SimulationDeok Yong Yoon, SeungHwan Lee, In-Jin Jang, et al.
Clinical and Translational Science|April 25, 2023
Safety, tolerability, pharmacokinetic/pharmacodynamic characteristics of bersiporocin, a novel prolyl-tRNA synthetase inhibitor, in healthy subjectsMin Young Park, Sungyeun Bae, Jung A Heo, et al.
Expert Opinion on Investigational Drugs|March 15, 2017
A randomized, double-blind, single-dose, two-arm, parallel study comparing pharmacokinetics, immunogenicity and tolerability of branded adalimumab and its biosimilar LBAL in healthy male volunteersKyoung Ryun Park, Hyewon Chung, Sung Mo Yang, et al.
International Journal of Clinical Pharmacology and Therapeutics|August 3, 2012
Multiple-dose pharmacokinetics of fesoterodine sustained-release in healthy Korean volunteersDongseong Shin, Kwang-Hee Shin, SeungHwan Lee, et al.
Clinical and Translational Science|May 3, 2024
Pharmacokinetic interactions between fexuprazan, a potassium-competitive acid blocker, and nonsteroidal anti-inflammatory drugs in healthy malesHeejae Won, Eunwoo Kim, Jihye Chae, et al.
Clinical Therapeutics|September 17, 2024
Pharmacokinetics and Pharmacodynamics of a Fixed-Dose Combination of Esomeprazole and Magnesium Hydroxide Compared to the Enteric-Coated EsomeprazoleYoonjin Kim, Sungyeun Bae, Inseung Jeon, et al.
CPT: Pharmacometrics & Systems Pharmacology|October 28, 2024
Population pharmacokinetic and pharmacodynamic model of evogliptin: Severe uremia increases the bioavailability of evogliptinByungwook Kim, Jung Eun Kim, Soyoung Lee, et al.
The Journal of Antimicrobial Chemotherapy|October 26, 2017
Safety, tolerability and pharmacokinetics of 21 day multiple oral administration of a new oxazolidinone antibiotic, LCB01-0371, in healthy male subjectsYewon Choi, Sang Won Lee, Anhye Kim, et al.
Pageof 30

Showing results (121-130 of 292) with videos related to

Sort By:
Pageof 30
Pharmaceuticals (Basel, Switzerland)|November 10, 2022
Safety, Tolerability, and Serum/Tear Pharmacokinetics of Human Recombinant Epidermal Growth Factor Eyedrops in Healthy SubjectsHyounggyoon Yoo, Seonghae Yoon, In-Jin Jang, et al.
Drug Design, Development and Therapy|February 14, 2015
A fixed-dose combination tablet of gemigliptin and metformin sustained release has comparable pharmacodynamic, pharmacokinetic, and tolerability profiles to separate tablets in healthy subjectsSang-In Park, Howard Lee, Jaeseong Oh, et al.
Pharmaceutics|September 28, 2021
Prediction of Drug-Drug Interaction Potential of Tegoprazan Using Physiologically Based Pharmacokinetic Modeling and SimulationDeok Yong Yoon, SeungHwan Lee, In-Jin Jang, et al.
Clinical and Translational Science|April 25, 2023
Safety, tolerability, pharmacokinetic/pharmacodynamic characteristics of bersiporocin, a novel prolyl-tRNA synthetase inhibitor, in healthy subjectsMin Young Park, Sungyeun Bae, Jung A Heo, et al.
Expert Opinion on Investigational Drugs|March 15, 2017
A randomized, double-blind, single-dose, two-arm, parallel study comparing pharmacokinetics, immunogenicity and tolerability of branded adalimumab and its biosimilar LBAL in healthy male volunteersKyoung Ryun Park, Hyewon Chung, Sung Mo Yang, et al.
International Journal of Clinical Pharmacology and Therapeutics|August 3, 2012
Multiple-dose pharmacokinetics of fesoterodine sustained-release in healthy Korean volunteersDongseong Shin, Kwang-Hee Shin, SeungHwan Lee, et al.
Clinical and Translational Science|May 3, 2024
Pharmacokinetic interactions between fexuprazan, a potassium-competitive acid blocker, and nonsteroidal anti-inflammatory drugs in healthy malesHeejae Won, Eunwoo Kim, Jihye Chae, et al.
Clinical Therapeutics|September 17, 2024
Pharmacokinetics and Pharmacodynamics of a Fixed-Dose Combination of Esomeprazole and Magnesium Hydroxide Compared to the Enteric-Coated EsomeprazoleYoonjin Kim, Sungyeun Bae, Inseung Jeon, et al.
CPT: Pharmacometrics & Systems Pharmacology|October 28, 2024
Population pharmacokinetic and pharmacodynamic model of evogliptin: Severe uremia increases the bioavailability of evogliptinByungwook Kim, Jung Eun Kim, Soyoung Lee, et al.
The Journal of Antimicrobial Chemotherapy|October 26, 2017
Safety, tolerability and pharmacokinetics of 21 day multiple oral administration of a new oxazolidinone antibiotic, LCB01-0371, in healthy male subjectsYewon Choi, Sang Won Lee, Anhye Kim, et al.
Pageof 30